Compare PLSE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | 2015 | 2007 |
| Metric | PLSE | CDNA |
|---|---|---|
| Price | $51.71 | $86.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $62.33 | ★ $65.33 |
| AVG Volume (30 Days) | 360.8K | ★ 1.3M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.45 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $480.71 | $30.36 |
| Revenue Next Year | $177.98 | $6.23 |
| P/E Ratio | ★ N/A | $33.32 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $12.56 | $14.27 |
| 52 Week High | $58.90 | $73.43 |
| Indicator | PLSE | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 80.69 |
| Support Level | $49.01 | $17.30 |
| Resistance Level | $55.36 | N/A |
| Average True Range (ATR) | 3.17 | 4.65 |
| MACD | 0.34 | 0.93 |
| Stochastic Oscillator | 64.14 | 86.08 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.